<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092024000200080</article-id>
<article-id pub-id-type="doi">10.35366/116316</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tromboelastografía point of care en pacientes con neumonía grave por SARS-CoV-2 en la unidad de cuidados intensivos]]></article-title>
<article-title xml:lang="en"><![CDATA[Point of care thromboelastography in patients with severe pneumonia due to SARS-CoV-2 in the Intensive Care Unit]]></article-title>
<article-title xml:lang="pt"><![CDATA[Tromboelastografia point of care em pacientes com pneumonia grave por SARS-CoV-2 na Unidade de Terapia Intensiva]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Guerrero]]></surname>
<given-names><![CDATA[Edgar Xavier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montelongo]]></surname>
<given-names><![CDATA[Felipe de Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar Mendoza]]></surname>
<given-names><![CDATA[Alfonso]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Sánchez]]></surname>
<given-names><![CDATA[Giovanni]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Herrera Morales]]></surname>
<given-names><![CDATA[Blanca Estela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sharpe Borrego]]></surname>
<given-names><![CDATA[Elma Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Salud del Estado de México Hospital General «Las Américas» ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General Regional No. 196 ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Guadalajara Nutrición Clínica ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>38</volume>
<numero>2</numero>
<fpage>80</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092024000200080&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092024000200080&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092024000200080&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la infección por el nuevo coronavirus SARS-CoV-2 se ha caracterizado a nivel mundial por presentar una coagulopatía asociada a la severidad del cuadro con un aumento de la morbimortalidad. El estado inflamatorio severo secundario a la infección conduce a un trastorno grave de la hemostasia típicamente observado en pacientes con sepsis y se ha descrito recientemente como coagulopatía inducida por sepsis (SIC: sepsis induced coagulopathy). Esto ha sido escasamente documentado en los pacientes con infección por este nuevo coronavirus.  Material y métodos:  estudio prospectivo, en el cual se ingresó a pacientes con diagnóstico por PCR (Protein Chain Reaction) para infección por SARS-CoV-2 y neumonía grave por criterio de ATS (American Thoracic Society) Score, donde se realizó una tromboelastografía (TEG) a la cabecera del paciente (tromboelastografía point of care), en la Unidad de Cuidados Intensivos Adultos.  Resultados:  se observó tendencia a patrones de hipercoagulabilidad; el más frecuente (42% de las muestras estudiadas) fue el aumento de la amplitud máxima, que está asociada a hipercoagulabilidad plaquetaria y en 21.4% el tiempo de reacción (R) disminuido relacionado con hipercoagulabilidad enzimática.  Conclusiones:  la infección por este nuevo coronavirus induce un estado procoagulante al activar la plaqueta y el uso de antiagregante plaquetario pudiera estar recomendado. Los patrones de coagulación valorados en este estudio no se restringieron solo a hipercoagulabilidad plaquetaria, por lo que se requiere una mayor muestra para ser concluyentes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  infection by the new coronavirus SARS-CoV-2 has been characterized worldwide by presenting a coagulopathy associated with the severity of the condition with an increase in morbidity and mortality. The severe inflammatory state secondary to infection leads to a severe haemostasis disorder typically seen in patients with sepsis and has recently been described as sepsis induced coagulopathy (SIC). This has been poorly documented in patients with infection by this new coronavirus.  Material and methods:  a prospective study was carried out, in which patients diagnosed by PCR (Protein Chain Reaction) for SARS-CoV-2 infection and severe pneumonia by ATS (American Thoracic Society) Score criteria were admitted, where performed a thromboelastography (TEG) at the patient&#8217;s bedside (point of care thromboelastography), in the adult intensive care unit (ICU).  Results:  the results show a tendency to hypercoagulability patterns, the most frequent in 42% of the samples studied, was the increase in the maximum amplitude, which is associated with platelet hypercoagulability and in 21.4% the decreased reaction time ® related to enzymatic hypercoagulability.  Conclusions:  the infection by this new coronavirus induces a procoagulant state by activating the platelet and the use of platelet antiaggregant could be recommended. The hypercoagulability patterns assessed in this study were not restricted to platelet hypercoagulability, so a larger sample is required to be conclusive.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a infecção pelo novo coronavírus SARS-CoV-2 tem se caracterizado em todo o mundo por uma coagulopatia associada à gravidade da doença e ao aumento da morbidade e da mortalidade. O estado inflamatório grave secundário à infecção leva a um distúrbio grave da hemostasia, normalmente observado em pacientes com sepse, e foi recentemente descrito como coagulopatia induzida por sepse (CIS). Isso foi pouco documentado em pacientes com essa nova infecção por coronavírus.  Material e métodos:  foi realizado um estudo prospectivo, no qual pacientes diagnosticados por PCR (Protein Chain Reaction) para infecção por SARS-CoV-2 e pneumonia grave foram admitidos de acordo com os critérios do ATS (American Thoracic Society) score, onde foi realizada tromboelastografia (TEG) à beira do leito do paciente (tromboelastografia point of care), na Unidade de Terapia Intensiva (UTI) adulto.  Resultados:  os resultados mostram uma tendência a padrões de hipercoagulabilidade, o mais frequente em 42% das amostras estudadas foi o aumento da amplitude máxima, que está associado à hipercoagulabilidade plaquetária e em 21.4% a diminuição do R relacionado à hipercoagulabilidade enzimática.  Conclusões:  a infecção por esse novo coronavírus induz um estado pró-coagulante pela ativação das plaquetas e o uso de agente antiplaquetário poderia ser recomendado. Os padrões de coagulação avaliados neste estudo não se restringiram apenas à hipercoagulabilidade plaquetária, razão pela qual é necessária uma amostra maior para que seja conclusivo.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[tromboelastografía point of care]]></kwd>
<kwd lng="es"><![CDATA[neumonía severa]]></kwd>
<kwd lng="es"><![CDATA[hipercoagulabilidad plaquetaria]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[point of care thromboelastography]]></kwd>
<kwd lng="en"><![CDATA[severe pneumonia]]></kwd>
<kwd lng="en"><![CDATA[platelet hypercoagulability]]></kwd>
<kwd lng="pt"><![CDATA[COVID-19]]></kwd>
<kwd lng="pt"><![CDATA[tromboelastografia point of care]]></kwd>
<kwd lng="pt"><![CDATA[pneumonia grave]]></kwd>
<kwd lng="pt"><![CDATA[hipercoagulabilidade plaquetária]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel coronavirus from patients with pneumonia in China, 2019]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>727-33</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panigada]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bottino]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tagliabue]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Grasselli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Novembrino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chantarangkul]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2020</year>
<volume>18</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1738-42</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Siguret]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Veyradier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2020</year>
<volume>46</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1603-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berlin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gulick]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe Covid-19]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>383</volume>
<page-range>2451-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Metlay]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Waterer]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Anzueto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brozek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crothers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An official clinical practice guideline of the American Thoracic Society and infectious diseases Society of America]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2019</year>
<volume>200</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>e45-67</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nisio]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Kitamura]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey]]></article-title>
<source><![CDATA[BMJ Open]]></source>
<year>2017</year>
<volume>7</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Warkentin]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van der Poll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2019</year>
<volume>17</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1989-94</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galvez]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cortez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tromboelastografía: nuevos conceptos en la fisiología de la hemostasia y su correlación con la coagulopatía asociada al trauma]]></article-title>
<source><![CDATA[Rev Colomb Anestesiol]]></source>
<year>2012</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>224-30</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalil]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Metersky]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Klompas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muscedere]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sweeney]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases Society of America and the American Thoracic Society]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<volume>63</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>e61-e111</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mucha]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Dugar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McCrae]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Joseph]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bartholomew]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sacha]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulopathy in COVID-19: manifestations and management]]></article-title>
<source><![CDATA[Cleve Clin J Med]]></source>
<year>2020</year>
<volume>87</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>461-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulopathy of coronavirus disease 2019]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>2020</year>
<volume>48</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1358-64</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 update: Covid-19-associated coagulopathy]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2020</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>54-67</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gando]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Falanga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaneo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ISTH interim guidance on recognition and management of coagulopathy in COVID-19]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2020</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1023-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gattinoni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Taccone]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Carlesso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marini]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prone position in acute respiratory distress syndrome. rationale, indications, and limits]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2013</year>
<volume>188</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1286-93</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iba]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Connors]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Warkentin]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Thachil]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The unique characteristics of COVID-19 coagulopathy]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2020</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>360</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medcalf]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Keragala]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Myles]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrinolysis and COVID-19: a plasmin paradox]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2020</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2118-22</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Vogler]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Wohlauer]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Urban]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 Infection]]></article-title>
<source><![CDATA[J Am Coll Surg]]></source>
<year>2020</year>
<volume>231</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>193-203.e1</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouadma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lescure]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
<name>
<surname><![CDATA[Lucet]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Yazdanpanah]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Timsit]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>2020</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>579-82</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costanzo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Palumbo]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<name>
<surname><![CDATA[Ardita]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Antignani]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Arosio]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Failla]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia]]></article-title>
<source><![CDATA[J Vasc Surg Venous Lymphat Disord]]></source>
<year>2020</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>711-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Konstantinides]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Becattini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Geersing]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harjola]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía ESC 2019 para el diagnóstico y tratamiento de la embolia pulmonar aguda]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>497.e1-497.e58</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2020</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1094-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elizalde]]></surname>
<given-names><![CDATA[GJJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fortuna]]></surname>
<given-names><![CDATA[CJA]]></given-names>
</name>
<name>
<surname><![CDATA[Luviano]]></surname>
<given-names><![CDATA[GJA]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[RVM]]></given-names>
</name>
<name>
<surname><![CDATA[Mijangos]]></surname>
<given-names><![CDATA[MJC]]></given-names>
</name>
<name>
<surname><![CDATA[Olivares]]></surname>
<given-names><![CDATA[DEM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guía para la Atención del Paciente Crítico con Infección por COVID-19]]></article-title>
<source><![CDATA[Med Crit]]></source>
<year>2020</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-42</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ten Cate]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thrombosis management in times of COVID-19 epidemy; a dutch perspective]]></article-title>
<source><![CDATA[Thrombosis J]]></source>
<year>2020</year>
<volume>18</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bikdeli]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Madhavan]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chuich]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dreyfus]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Driggin]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2020</year>
<volume>75</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2950-73</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vivas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Esteve-Pastor]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Roldán]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tello-Montoliu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Nodar]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología [Recommendations on antithrombotic treatment during the COVID-19 pandemic. position statement of the working group on cardiovascular thrombosis of the spanish society of cardiology]]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>749-57</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Crowther]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gutterman]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Schuünemann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2012</year>
<volume>141</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>7S-47S</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lecompte]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Douxfils]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lessire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dogné]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Chatelain]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory]]></article-title>
<source><![CDATA[Thromb J]]></source>
<year>2020</year>
<volume>18</volume>
<page-range>17</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
